Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date β€” because we believe great analysis should be held accountable.

AllAAOIACADADMAAGIOALMSALMUALTSAPGEAUPHAVAVBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTRIGCTGOOGGPCRHALOHIMSHOODHWMIRENIVVDKALAKALVLENZLEVILITELRMRLULULUNRMDGLMESOMOHMTCHMUMVSTNBISNKENRIXNVAXOKUROLMAONCOSCRPHATPLRXPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHAUNHVEONVORWVEXFORZLAB
Apogee's stock soared 96% on strong trial data, valuing it at $6.5B. However, insiders are aggressively selling shares, signaling major risk for the pre-revenue biotech.

Priced for Perfection: The $6.5 Billion Question Hanging Over Apogee Therapeutics

2026-03-24BearishStrongChange from report: +18.2%

Apogee's stock soared 96% on strong trial data, valuing it at $6.5B. However, insiders are aggressively selling shares, signaling major risk for the pre-revenue biotech.